CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
- KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update.
- 05/15/2025
|
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
- BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884.
- 05/07/2025
|
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.
- KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estate development and construction.
- 05/06/2025
|
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
- BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update.
- 04/02/2025
|
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
- KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series E Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $1.0 million before deducting offering expenses. The offering closed on March 21, 2025.
- 03/24/2025
|
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
- BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.
- 02/27/2025
|
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
- David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO
- 01/03/2025
|
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
- BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder.
- 12/05/2024
|
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
- BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).
- 11/14/2024
|
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
- BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).
- 11/13/2024
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
- Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $7.35 per share a year ago.
- 11/12/2024
|
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
- BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update.
- 11/12/2024
|
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
- BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension until December 24, 2024, to regain compliance with Nasdaq's minimum stockholders equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule").
- 10/24/2024
|
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
- NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities
- 10/23/2024
|
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
- Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
- 10/09/2024
|
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
- - Patients are preselected for CDKN2A and/or CDKN2B abnormalities - - Safety and efficacy data to be reported at an upcoming oncology medical conference - BERKELEY HEIGHTS, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that enrollment of 12 patients has been completed as per protocol in Cohort 8 of its Phase 2 stage, proof of concept 065-101 study of fadraciclib (“fadra”), a CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma.
- 09/25/2024
|
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
- BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will be featured as a presenting company at the H.C.
- 09/04/2024
|
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
- BERKELEY HEIGHTS, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) and a hearing has been scheduled for October, 15, 2024.
- 09/03/2024
|
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Cyclacel Pharmaceuticals (CYCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 09/02/2024
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO Conference Call Participants Ahu Demir - Ladenburg Thalmann Grace Kim Good afternoon, everyone. And thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the second quarter ended June 30, 2024.
- 08/14/2024
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
- Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $6.60 per share a year ago.
- 08/14/2024
|
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
- BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2024 financial results on Wednesday, August 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
- 08/07/2024
|
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
- Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 07/25/2024
|
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
- BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor.
- 06/26/2024
|
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
- Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 06/06/2024
|
Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- - Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -
- 06/04/2024
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO Conference Call Participants Ahu Demir - Ladenburg Thalmann Operator Good afternoon and welcome to the Cyclacel Pharmaceuticals First Quarter 2024 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
- 05/14/2024
|
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
- BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
- 05/08/2024
|
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
- BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has closed its previously announced private placement for the purchase and sale of 4,968,945 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 4,968,945 shares of common stock and short-term series B warrants to purchase up to 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $1.36 per share and are exercisable immediately upon issuance. The series A warrants expire five and one-half years from the date of issuance and the short-term series B warrants expire eighteen months from the date of issuance.
- 05/02/2024
|
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?
- Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company withdrew a proposed public offering. A filing with the Securities and Exchange Commission (SEC) has the company withdrawing its proposed public offering filed in March.
- 04/30/2024
|
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,968,945 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 4,968,945 shares of common stock and short-term series B warrants to purchase up to 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.36 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 2, 2024, subject to the satisfaction of customary closing conditions.
- 04/30/2024
|
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
- - New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
- 04/01/2024
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
- 03/19/2024
|
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- – On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARCA-Mutated Cancers – – Management to Host Conference Call at 4:30 pm ET Today – BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.
- 03/19/2024
|
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
- BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call at 4:30pm ET on the same day.
- 03/13/2024
|
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma
- 03/07/2024
|
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
- BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&D costs incurred in the year ended December 31, 2023. The Company expects to receive an additional approximately $0.8 million following confirmation of a change in the rate of tax credit regarding 2023 expenditures.
- 03/06/2024
|
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
- BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.
- 02/20/2024
|
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
- BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company.
- 01/30/2024
|
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
- Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is falling on Tuesday but it's not due to any negative news from the clinical-stage biopharmaceutical company. Instead, shares of CYCC stock are retreating after undergoing a rally on Monday.
- 01/09/2024
|
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
- BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.
- 01/08/2024
|
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
- BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.
- 01/02/2024
|
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
- BERKELEY HEIGHTS, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company will also issue unregistered warrants to purchase up to 388,200 shares of common stock with an exercise price of $3.19 per share which will be immediately exercisable for a period of seven years following issuance. The closing of the offering is expected to occur on or about December 26, 2023, subject to the satisfaction of customary closing conditions.
- 12/22/2023
|
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
- - Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after One Cycle - - Retrospective Analysis Identified CDKN2A, CDKN2B and/or MTAP Deletions in Four Patients Previously Dosed with Fadra Achieving Responses or Stable Disease - - Forthcoming Phase 2 Study to Further Evaluate Fadra Efficacy - BERKELEY HEIGHTS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today interim results from its Phase 1, dose escalation 065-101 study of fadraciclib (“fadra”) in patients with advanced solid tumors and lymphoma.
- 12/18/2023
|
Cyclacel Pharmaceuticals Announces Reverse Stock Split
- BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (“Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on Friday, December 15, 2023. The Reverse Stock Split, which was approved by stockholders at the Company's Special Meeting of Stockholders on December 8, 2023, is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. Beginning with the opening of trading on Monday, December 18, 2023, the Company's common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the existing symbol “CYCC” and a new CUSIP number 23254L801.
- 12/12/2023
|
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
- BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), by filing its quarterly report on Form 10-Q for the period ended September 30, 2023, on November 29, 2023 with the Securities and Exchange Commission.
- 11/30/2023
|
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
- BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2023 financial results on Monday, November 13, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day.
- 11/07/2023
|
New Strong Buy Stocks for October 17th
- MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
- 10/17/2023
|
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
- BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
- 08/03/2023
|
Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript
- Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu Demir - Ladenburg Thalmann Shubhendu Sen Roy - Brookline Capital Markets Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2023 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
- 05/11/2023
|
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
- BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2023 financial results on Thursday, May 11, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
- 05/04/2023
|
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
- BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.
- 03/07/2023
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Irina Koffler - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Ahu Demir - Ladenburg Jeff Jones - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Good afternoon and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full Year 2022 Results Conference Call and Webcast. [Operator Instructions] Please note, today's call is being recorded.
- 03/06/2023
|
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
- BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2022 financial results on Monday, March 6, 2023. The Company will host a conference call at 4:30pm ET on the same day.
- 02/27/2023
|
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
- BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present an overview of Cyclacel's business and clinical programs at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis Times Square on February 6-9, 2023.
- 01/30/2023
|
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
- BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events are taking place January 9-11, 2023 in San Francisco, California.
- 12/15/2022
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President & Chief Executive Officer Mark Kirschbaum - Senior Vice President & Chief Medical Officer Paul McBarron - Executive Vice President, Finance & Chief Operating Officer Conference Call Participants Ahu Demir - Ladenburg Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2022 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
- 11/09/2022
|
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
- BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2022 financial results on Wednesday, November 9, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day.
- 11/03/2022
|
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
- - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma -
- 10/13/2022
|
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
- BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann's 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York.
- 09/21/2022
|
Penny Stocks To Buy Now? 4 Biotech Stocks To Watch This Week
- Hot biotech penny stocks to watch thanks to MNMD stock today. The post Penny Stocks To Buy Now?
- 08/18/2022
|
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2022 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Chief Financial Officer and Chief Operating Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann & Co Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2022 Results Conference Call and Webcast. [Operator Instructions].
- 08/10/2022
|
Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis
- Cyclacel Pharmaceuticals is an oncology company with two major value drivers in Phase 1/2 trials and overdue catalysts. It trades at an $11 million market cap, with last reported cash of $34.5 million, and mean analyst estimate shows a +1,500% rise potential.
- 08/07/2022
|
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
- BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results on Wednesday, August 10, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
- 08/03/2022
|
What Are Penny Stocks & 3 To Buy According To Analysts In July
- Penny stocks to buy according to analysts. The post What Are Penny Stocks & 3 To Buy According To Analysts In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/18/2022
|
Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients
- Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities. Fifteen patients with.
- 06/30/2022
|
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2022 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President, CEO & Executive Director Paul McBarron - EVP, CFO, COO, Secretary & Executive Director Mark Kirschbaum - SVP & Chief Medical Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Ahu Demir - Ladenburg Thalmann & Co. Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2022 Results Conference Call and Webcast. [Operator Instructions].
- 05/11/2022
|
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript
- 03/28/2022
|
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript
- 08/11/2021
|
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results - Earnings Call Transcript
- 05/12/2021
|
Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference
- BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference, a virtual event, on Thursday, March 18, 2021 at 9:20 AM (EDT). Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. Cyclacel will host one-on-one meetings with investors during the event.
- 03/15/2021
|
Cyclacel Pharmaceuticals Presses Capital Raise Button
- Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) priced an underwritten public offering of 1.81 million common shares at $7 per share, a discount of 11% on the last close price of $7.87 on Thursday. It will raise gross proceeds of approximately $12.65 million.
- 03/12/2021
|
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call Transcript
- 02/25/2021
|
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
- – Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures –
- 01/11/2021
|
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
- BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech Showcase™ Digital 2021. The conference is taking place online between January 11-15 and will feature prerecorded sessions of company presentations. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs.
- 12/30/2020
|
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript
- 11/11/2020
|
Cyclacel Pharmaceuticals to Release Third Quarter Financial Results
- BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results on Wednesday, November 11, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
- 11/05/2020
|
Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020
- A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib
- 10/26/2020
|
Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results
- \- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -BERKELEY HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2020 and business highlights, including an update on its progress with fadraciclib, Cyclacel's novel CDK2/9 inhibitor. The Company's net loss applicable to common shareholders for the three months ended June 30, 2020 was $2.2 million. As of June 30, 2020, cash and cash equivalents totaled $25.3 million. Based on current spending, the Company estimates it has sufficient resources to fund planned operations, including research and development, through the end of 2022.“We believe fadraciclib is establishing a leadership position among MCL1 suppressing compounds in development. Our recent, peer-reviewed publication elaborates the mechanistic rationale for fadraciclib as an anti-cancer therapy signifying the benefits of inhibiting CDK2 and CDK9, two complementary cancer pathways,” said Spiro Rombotis, President and Chief Executive Officer. “We continue to be encouraged by observations of deep partial response and prolonged stable disease with tumor shrinkage as an intravenously administered monotherapy in patients with advanced solid tumors and antileukemic activity in combination with venetoclax. In parallel with evaluating fadraciclib in certain leukemias, we are executing a precision medicine strategy to evaluate the compound in patients with solid tumors with study enrollment expected to begin by the first quarter of 2021. As the global pandemic continues to unfold, our priorities are to ensure patient and employee safety and support efforts to stem COVID-19 disease as part of our corporate social responsibility. Despite the challenges we remain committed to our strategy of building an innovative pipeline addressing the rising problem of cancer resistance and achieving our clinical milestones to drive shareholder value.”Key Corporate Highlights * Announced publication of a peer-reviewed study of fadraciclib, in PLOS ONE. The publication, authored by scientists from Cyclacel and The Institute of Cancer Research, London, describes the discovery of fadraciclib and shows its ability to target CDK2 and CDK9, leading to broad therapeutic potential. * CYC065-01 Phase 1 part 2 single agent i.v. – As previously reported a heavily pretreated patient with MCL1 amplified endometrial cancer achieved a radiographically confirmed partial response (PR) after a month and a half on fadraciclib at 213mg. This patient continues on therapy for more than a year and reduction in her target tumor lesions is 83%. An additional patient with cyclin E amplified ovarian cancer achieved stable disease with 29% tumor shrinkage after approximately four months at 213mg. We have submitted data for publication at a cancer conference later in the year. * Based on data thus far, we are designing a Phase 1/2 precision medicine study to further evaluate fadraciclib as monotherapy and in combinations in patients with advanced solid tumors. * CYC065-01 Phase 1 part 3 single agent p.o. - Initial data from an oral capsule formulation of fadraciclib given once daily to four patients with advanced solid tumors demonstrated a predictable pharmacokinetic profile closely overlapping the intravenous form with encouraging exposure levels. * CYC065-03 Phase 1 fadraciclib i.v. and venetoclax p.o. in AML/MDS - We have dosed 11 heavily pretreated patients with relapsed/refractory (R/R) AML in five dose levels up to 200 mg/m2 of fadraciclib in combination with venetoclax. Evidence of anticancer activity has been observed in four out of eleven patients treated. Preclinical data in AML suggest that targeting both MCL1 and BCL2 may be more beneficial than inhibiting either protein alone. * CYC065-02 Phase 1 fadraciclib i.v. and venetoclax p.o. in CLL - We have dosed 5 patients with R/R CLL in four dose levels up to 150 mg/m2 of fadraciclib in combination with venetoclax. Evidence of anticancer activity has been observed in two patients who achieved MRD negativity on the combination. Preclinical data suggest that targeting both BCL2 and MCL1 in CLL may be more beneficial than single agent treatment in this setting as well. * CYC682-11 Phase 1 part 2 sapacitabine p.o. and venetoclax p.o. - We have enrolled 12 patients in a dose escalation study in our DNA Damage Response (DDR) program evaluating an oral combination of sapacitabine and venetoclax in patients with R/R AML/MDS. Two patients, previously treated with combination therapies including hypomethylating agents, have achieved 5 and 6 cycles of treatment respectively. Sapacitabine is a nucleoside analogue that is active in AML and MDS R/R to prior therapy such as cytarabine or hypomethylating agents. Preclinical data demonstrated synergy of sapacitabine with BCL2 inhibition, which may offer an effective, oral treatment regimen for patients who have failed front-line therapy. * CYC140-01 Phase 1 CYC140 i.v. - We have enrolled 6 patients in our first-in-human, dose escalation study evaluating CYC140 in patients with advanced leukemias. CYC140 is a small molecule, selective polo-like-kinase 1 (PLK1) inhibitor that has demonstrated potent and selective target inhibition and high activity in xenograft models of human cancers. In addition to hematological malignancies we are evaluating studies of CYC140 in solid tumors.More information on our clinical trials can be found here.Key Business Objectives * Report updated fadraciclib Phase 1 safety and efficacy data with frequent i.v. dosing schedule in patients with advanced solid cancers; * Report initial safety and PK data from Phase 1 study of fadraciclib oral formulation; * Treat first patient in fadraciclib Phase 1/2 precision medicine study; * Report initial data from fadraciclib-venetoclax Phase 1 study in R/R AML/MDS & CLL; * Report initial data from sapacitabine-venetoclax Phase 1 study in R/R AML/MDS; * Report initial data from CYC140 Phase 1 first-in-human study in R/R leukemias; and * Report data from Phase 1b/2 sapacitabine-olaparib IST in BRCA mutant metastatic breast cancer when reported by the investigators.Financial HighlightsAs of June 30, 2020, cash and cash equivalents totaled $25.3 million, compared to $11.9 million as of December 31, 2019. The increase of $13.4 million was primarily due to net proceeds of $18.3 million from an equity financing in April 2020 and net cash used in operating activities of $4.7 million. There were no revenues for each of the three months ended June 30, 2020 and 2019.Research and development expenses were $1.2 million for each of the three months ended June 30, 2020 and 2019. Research and development expenses relating to transcriptional regulation increased by approximately $0.2 million for the three months ended June 30, 2020 as we continue to progress the clinical evaluation of fadraciclib.General and administrative expenses for the three months ended June 30, 2020 were $1.3 million, compared to $1.2 million for the same period of the previous year.Total other income, net, for the three months ended June 30, 2020 was $20,000, compared to $0.2 million for the same period of the previous year. The decrease of approximately $0.2 million for the three months ended June 30, 2020 is primarily related to income received under an Asset Purchase Agreement with Thermo Fisher Scientific Inc.United Kingdom research & development tax credits were $0.3 million for each of the three months ended June 30, 2020 and 2019.Net loss for the three months ended June 30, 2020 was $2.2 million compared to $1.8 million for the same period in 2019.The Company estimates that cash resources of $25.3 million as of June 30, 2020 will fund currently planned programs through 2022.Conference call information:US/Canada call: (877) 493-9121 / international call: (973) 582-2750 US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406 Code for live and archived conference call is 2477369.For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days. About Cyclacel Pharmaceuticals, Inc.Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology. The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors and in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is evaluating an oral combination of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An investigator-sponsored trial (IST) is evaluating an oral combination of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced leukemias/MDS patients. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com.Forward-looking StatementsThis news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
- 08/12/2020
|
Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results
- BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results on Wednesday, August 12, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call: (877) 493-9121 / international call: (973) 582-2750 US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406 Code for live and archived conference call is 2477369.For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days. About Cyclacel Pharmaceuticals, Inc.Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology. The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors and in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is evaluating an oral combination of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An investigator-sponsored trial (IST) is evaluating an oral combination of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced leukemias/MDS patients. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com.Forward-looking StatementsThis news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts for Cyclacel Pharmaceuticals, Inc.Company: Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com Investor Relations: Russo Partners LLC, Jan Medina, (646) 942-5632, Jan.Medina@russopartnersllc.com© Copyright 2020 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
- 08/05/2020
|
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
- Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
- 07/28/2020
|
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock Passes Above 200 Day Moving Average of $2.43
- Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.43 and traded as high as $4.59. Cyclacel Pharmaceuticals shares last traded at $4.44, with a volume of 107,800 shares changing hands. A number of research […]
- 07/14/2020
|
Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer
- \-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1,.
- 07/13/2020
|
VITRAC Therapeutics Initiated Global Clinical Development of VIC-1911, licensed from Taiho Pharmaceutical
- VITRAC Therapeutics, LLC (VITRAC) initiated the global clinical development of VIC-1911, an oncology candidate formally known as TAS-119, which was li
- 06/29/2020
|
CDK Global Inc (NASDAQ:CDK) Shares Bought by Nuveen Asset Management LLC
- Nuveen Asset Management LLC grew its stake in shares of CDK Global Inc (NASDAQ:CDK) by 26.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 646,924 shares of the software maker’s stock after acquiring an additional 135,374 shares during […]
- 06/17/2020
|
CDK Global Inc (NASDAQ:CDK) Shares Sold by Alliancebernstein L.P.
- Alliancebernstein L.P. cut its position in shares of CDK Global Inc (NASDAQ:CDK) by 0.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,156,529 shares of the software maker’s stock after selling 1,229 shares during the period. Alliancebernstein L.P. owned 0.95% of CDK Global worth […]
- 06/15/2020
|
CDK Global Inc (NASDAQ:CDK) Shares Acquired by Pictet Asset Management Ltd.
- Pictet Asset Management Ltd. lifted its holdings in shares of CDK Global Inc (NASDAQ:CDK) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,014 shares of the software maker’s stock after buying an additional 600 shares during the […]
- 06/14/2020
|
34 Stocks Moving in Wednesday's Pre-Market Session
|
Edited Transcript of CYCC earnings conference call or presentation 12-May-20 8:30pm GMT
- Q1 2020 Cyclacel Pharmaceuticals Inc Earnings Call
- 06/09/2020
|
AWS CDK for Beginners
- The intended audience for this article is someone who is either new to Amazon Web Services (AWS) or AWS Cloud Development Kit (CDK).
- 05/23/2020
|
3 Biotech Stocks Under $5 With Massive Upside Potential
- Is it May 2020 or March 2009? As Wall Street observers traverse the confused economic environment, flashbacks of the Great Recession are coming to mind.
- 05/21/2020
|
3 “Strong Buy” Biotech Stocks Under $5 With Massive Upside Potential
- Is it May 2020 or March 2009? As Wall Street observers traverse the confused economic environment, flashbacks of the Great Recession are coming to mind. Those looking at the glass half empty will point out the bear market that emerged took 18 months to reach the lowest point. However, the optimists are singing a different tune.Among the bulls is Morgan Stanley’s head of U.S. equity strategy, Michael Wilson. In a recent note to clients, he argues that the current state of the market bears a striking resemblance to March 2009, the period in which the U.S. economy began to recover, with the S&P; 500 embarking on what would become the longest bull-market run on record.“Markets are tracking the Great Financial Crisis period very closely in many ways,” Wilson wrote. To support this claim, the strategist highlights the fact that stocks are bouncing back in a “similar pattern," at the same time the amount of stocks, especially cyclicals, that have exceeded their 200-day moving average is on the rise. This is important as cyclicals usually lead the charge when a market recovery kicks off. Wilson also notes that the equity-risk premium, or the expected earnings yield for the S&P; 500 minus the ten-year Treasury yield, looks the same as it did in March 2009, which played into his decision to call a stock-market bottom on March 16 of this year.Taking Wilson’s views into consideration, risk-tolerant investors are on the hunt for promising names now trading at lower levels, specifically within the biotech space. As it just takes one positive catalyst like strong data or a favorable FDA ruling to send shares skyrocketing, massive returns are on the table. That being said, as the opposite also holds true, these stocks come with their fair share of risk.Acknowledging the risk involved, we used TipRanks’ database to pinpoint compelling, yet affordable biotech stocks. We found three trading for under $5 that have not only received enough bullish recommendations from analysts to earn a “Strong Buy” consensus rating, but also sport colossal upside potential.Gamida Cell Ltd. (GMDA)It has certainly been a rough week for Gamida Cell, which develops therapies that could potentially cure blood cancers and other blood diseases.On Tuesday, the company unveiled the pricing for its underwritten public offering of 13,333,334 ordinary shares, which landed at $4.50 per share. The fund raise sent shares tumbling, with GMDA walking away from the day’s trading session down 26%. However, the new share price, $4.42, offers an attractive entry point, according to the analyst community.Weighing in for Oppenheimer, five-star analyst Mark Breidenbach cites recently released positive top-line data from its randomized Phase 3 trial of omidubicel in patients receiving bone marrow transplants as a key component of his bullish thesis. The trial had 125 participants between the ages of 12-65 with high-risk hematologic malignances (AML, CML, MDS, lymphoma), and GMDA’s candidate was studied against standard umbilical cord blood (UCB) grafts.Not only did omidubicel meet its primary endpoint, but the asset’s failure rate came in at 4% while the UCBs had a failure rate of 12%. After the readout, the company announced that it plans on initiating a rolling BLA submission in the fourth quarter.Expounding on the implications of the results, Breidenbach stated, “While expecting to see full results are at a medical meeting later this year (likely ASH), we believe these data could support a 2021 FDA approval and help spur uptake at transplant centers.” He added, “We believe omidubicel has been de-risked with the successful Phase 3 results.”Adding to the good news, Breidenbach argues that the results show omidubicel is “competitive with more widely used grafts, including matched unrelated donor (MUD) and mismatched-related donor grafts.” He noted, “As such, these data may support wider adoption of omidubicel among transplant physicans, although longer follow-up will be required to assess relapse rates and treatment-related mortality.”Based on all of the above, Breidenbach keep an Outperform (i.e. Buy) rating on the stock. Along with his bullish call, he also bumped up the price target from $18 to $20. This implies upside potential of a massive 352%. (To watch Breidenbach’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. Only Buy ratings have been received in the last three months, 3, in fact, so the consensus rating is a Strong Buy. In addition, the $18 average price target puts the upside potential at 307%. (See Gamida Cell stock analysis on TipRanks)VBI Vaccines (VBIV)Using its enveloped virus-like particle (eVLP) platform, VBI Vaccines develops vaccines that could be capable of addressing unmet needs in infectious disease and immuno-oncology. With one analyst, Canaccord Genuity’s John Newman, expecting a “catalyst-rich” second half of the year for the company, its $2.49 share price could mean that now is the time to pull the trigger.The five-star analyst tells investors the fourth quarter of 2020 will see VBIV submit regulatory approval filings for Sci-B-Vac, its vaccine against hepatitis B. These will be comprised of data from the CONSTANT and PROTECT Phase 3 trials in the U.S., Europe and Canada. “We continue to expect the agencies will view Sci-B-Vac's regulatory applications favorably and expect approvals in 2021...We continue to believe a key factor for VBIV will be whether the Advisory Committee on Immunization Practices (ACIP) recommends Sci-B-Vac at a two-dose immunization schedule, for their commercial launch,” he commented.As for its chronic hepatitis B virus (HBV) therapy, VBI-2601, initial human proof-of-concept data from the Phase 1b/2a study could be published in the second half of this year as well.Looking at its VBI-1901 asset, which was designed for use in recurrent Glioblastoma Multiforme (rGBM) patients, expanded immunologic, tumor and clinical data from the GM-CSF arm and initial immunologic and tumor response data from the AS01B arm are slated for release mid-year and in Q4, respectively. “We look for continued positive data for VBI-1901 in GBM,” Newman said.If that wasn’t enough, a pan-coronavirus vaccine is in the works, with VBIV expecting IND-enabling animal testing for the candidate, VBI-2901, to start in the second quarter. On top of this, the company could have clinical candidates selected and enough clinical supply ready in Q4 2020.As VBIV’s operations through 2021 will most likely be supported by the $57.5 million equity raise last month and its $35.8 million in cash as of Q1 2020, it’s no wonder Newman is optimistic. In addition to maintaining a Buy recommendation, he did trim the price target by $1 to account for share dilution. That being said, the $3 figure still leaves room for a possible twelve-month gain of 20%. (To watch Newman’s track record, click here)Do other analysts agree with Newman? As it turns out, they do. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: VBIV is a Strong Buy. At $4.33, the average price target is more aggressive and suggests 74% upside potential. (See VBI Vaccines stock analysis on TipRanks)Cyclacel Pharmaceuticals (CYCC)The last biotech on our list, Cyclacel Pharmaceuticals, uses cell cycle, transcriptional regulation and DNA damage response biology to develop cancer therapies. Currently going for $4.59 apiece, some members of the Street are telling investors to get onboard before shares take off on an upward trajectory.Writing for Roth Capital, analyst Jonathan Aschoff believes the strength of CYCC’s development program makes it a stand-out. The company is focused on solid tumors, with it conducting its clinical trials so that it can still report updated fadraciclib Phase 1 data with the higher frequency IV dosing schedule in advanced solid tumors, initial Phase 1 safety and PK results with oral fadraciclib as well as kick off its Phase 1/2 precision medicine trial in early 2021. It should be noted that oral fadraciclib has already demonstrated concordance with IV pharmacokinetics based on early clinical data.With this strong technology, Aschoff argues that CYCC is targeting the unmet need in the cyclin E overexpressing tumors of the breast, endometrium/uterus and ovaries space. “The solid tumor program is key to our CYCC valuation, as projected revenue from this cyclin E overexpressing population represents more than 70% of projected revenue. We note that cyclin E is overexpressed in one-third of HR+ breast cancer patients resistant to first-line therapy, where patients could receive fadraciclib alone or potentially in combination with hormonal therapy. This population, combined with resistant second-line ovarian and endometrial/uterine cancer patients with high cyclin E amount to just over 100,000 patients in the U.S.,” he explained.Additionally, CYCC is set to publish initial Phase 1 fadraciclib/ venetoclax results in rel/ref AML/MDS and CLL, initial Phase 1 sapacitabine/venetoclax results in rel/ref AML/MDS and initial Phase 1 CYC140 data in advanced leukemias. While Phase 1b/2 sapacitabine/olaparib results in BRCA mutant metastatic breast cancer are also expected, the timing is uncertain.Some investors have expressed concern regarding COVID-19's impact on the company’s trials, but Aschoff points out that thus far, CYCC hasn’t experienced any enrollment delays. He added, “CYCC recently announced its intent to study the potential of fadraciclib to be an early inhibitor of the detrimental inflammatory response observed in COVID-19 patients, specifically to induce MCL1 downregulation and apoptosis of inflammatory neutrophils.”Consider all of this combined with its $27.
- 05/21/2020
|
Cyclacel Pharma Shares Spike To Session High, Up 4.6%; Hearing Research Firm Brookline Initiated Coverage On Stock With Buy Rating, $22 Price Target
|
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2020 Results - Earnings Call Transcript
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2020 Results Earnings Conference Call May 12, 2020, 04:30 PM ET Company Participants Jan Medina - Investor Relat
- 05/13/2020
|
Cyclacel Pharmaceuticals Q1 EPS $(2.770) Beats $(2.900) Estimate
|
Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results
- - Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - - Following Recent Financing Cash Runway to End of 2022 - BERKELEY HEIGHTS, N.J., May 12, 2020 -- Cyclacel.
- 05/12/2020
|
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
- 05/12/2020
|
Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results
- BERKELEY HEIGHTS, N.J., May 05, 2020 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- 05/05/2020
|
Cyclacel Pharmaceuticals On April 29, Was Notified By Nasdaq That Co Has Evidenced Full Compliance With All Criteria For Continued Lisiting
|
Fly Intel: Top five analyst initiations FGEN;SLRX;GMDA;KRUS;CYCC
- Fly Intel: Top five analyst initiations FGEN SLRX GMDA KRUS CYCC
- 04/27/2020
|
JPMorgan construction analysts to hold an amalyst/industry conference call
- JPMorgan construction analysts to hold an amalyst/industry conference call
- 04/27/2020
|
JPMorgan basic materials analysts to hold an analyst/industry conference call
- JPMorgan basic materials analysts to hold an analyst/industry conference call
- 04/27/2020
|
Cyclacel Announces Closing of $20 Million Public Offering
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced public offering of (i) 4,000,000 shares of its common stock (or
- 04/24/2020
|
Pesistance Pays: How I've Kept April's Green Streak Alive
- My all-green April continues! After some big wins and a few close calls, I've managed to keep my green streak alive at 16 days and add another $20,000 to the month's total. I'm actually well above pace for the month and could likely pass $70 or even $80 thousand if things keep going as they
- 04/24/2020
|
Pesistance Pays: How I've Kept April's Green Streak Alive
- My all-green April continues! After some big wins and a few close calls, I’ve managed to keep my green streak alive at 16 days and add another $20,000 to the month’s...
- 04/24/2020
|
The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks htitting 52-week highs April 22.) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Johnson & Johnson (NYSE: JNJ) (reacted to a sell-side upgrade) * Cue Biopharma Inc (NASDAQ: CUE)
- 04/23/2020
|
The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Arvinas Inc (NASDAQ: ARVN) * Exelixis, Inc. (NASDAQ: EXEL
- 04/22/2020
|
52 Biggest Movers From Yesterday
|
The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 21)
Alnylam Pharmaceuticals,...
- 04/22/2020
|
Mid-Afternoon Market Update: Dow Slides 500 Points; Vaxart Shares Spike Higher
- Toward the end of trading Tuesday, the Dow traded down 2.1% to 23,150 while the NASDAQ fell 2.44% to 8,351.77. The S&P also fell, dropping 2.44% to 2,754.16.
The U.S. is the...
- 04/21/2020
|
Company News for Apr 21, 2020
- Companies In The News Are: CYCC, CODX, NBY, EXEL
- 04/21/2020
|
Company News for Apr 21, 2020
- Companies In The News Are: CYCC, CODX, NBY, EXEL
- 04/21/2020
|
44 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
The Peck Company Holdings, Inc. (NASDAQ: PECK) shares climbed 68.5% to $4.50.
Core Molding Technologies, Inc. (NYSE: CMT) gained 35.1% to $3.2429.
TriState Capital...
- 04/21/2020
|
Mid-Day Market Update: TriState Capital Jumps Following Q1 Results; Cyclacel Pharmaceuticals Shares Plunge
- Midway through trading Tuesday, the Dow traded down 2.88% to 22968.65 while the NASDAQ fell 3.94% to 8223.52. The S&P also fell, dropping 3.30% to 2730.00.
The U.S. is the...
- 04/21/2020
|
Mid-Morning Market Update: Markets Open Lower; Coca-Cola Tops Q1 Estimates
- Following the market opening Tuesday, the Dow traded down 1.8% to 23224.37 while the NASDAQ fell 2.04% to 8386.31. The S&P also fell, dropping 1.89% to 2,769.81.
The U.S. is...
- 04/21/2020
|
BKR, FCX among premarket losers
- Cyclacel Pharmaceuticals (NASDAQ:CYCC) -53% on equity offering.Summit Wireless Technologies (NASDAQ:WISA) -14%.Sibanye Stillwater (NYSE:SBSW) -14%.NovaBay Pharmaceuticals (NYSEMKT:NBY) -11%.Avita Medi
- 04/21/2020
|
CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of a public offering with expected total gross proceeds of approximately $20 million, before
- 04/21/2020
|
78 Biggest Movers From Yesterday
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.67%
- U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.67%
- 04/21/2020
|
Mid-Afternoon Market Update: Dow Falls Over 400 Points; NovaBay Pharmaceuticals Shares Jump
- Toward the end of trading Monday, the Dow traded down 1.79% to 23807.82 while the NASDAQ fell 0.49% to 8607.34. The S&P also fell, dropping 1.28% to 2837.73.
The U.S. is the...
- 04/20/2020
|
55 Stocks Moving In Monday's Mid-Day Session
- Gainers
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) shares climbed 93.6% to $12.41 after the company announced a collaboration agreement with the University of Edinburgh to...
- 04/20/2020
|
Mid-Day Market Update: Crude Oil Plunges 45%; Cyclacel Pharmaceuticals Shares Jump
- Midway through trading Monday, the Dow traded down 0.71% to 24,070.23 while the NASDAQ rose 0.35% to 8,680.06. The S&P also fell, dropping 0.28% to 2,866.43.
The U.S. is the...
- 04/20/2020
|
Stocks That Hit 52-Week Highs On Monday
- On Monday, 38 companies hit new 52-week highs.
Things to Consider:
The largest company by market cap to hit a new 52-week high was Walmart (NYSE: WMT).
The company with...
- 04/20/2020
|
Mid-Morning Market Update: Markets Open Lower ; Halliburton Earnings Top Views
- Following the market opening Monday, the Dow traded down 1.41% to 23901.55 while the NASDAQ fell 0.48% to 8608.89. The S&P also fell, dropping 1.03% to 2844.82.
The U.S. is...
- 04/20/2020
|
35 Stocks Moving in Monday's Pre-Market Session
- Gainers
American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) shares rose 191.2% to $5.97 in pre-market trading after the company announced collaboration with Cytiva on COVID-...
- 04/20/2020
|
Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease
- BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom, April 20, 2020 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a.
- 04/20/2020
|
Nano-Cap Cyclacel Rockets Higher On Launch Of Study For Coronavirus Inflammation
- Shares of nanocap biopharma Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) were ripping higher Monday following the announcement of a partnership to study two of its drugs...
- 04/20/2020
|
Weekly Summary Corporate dividends, name changes, new listings
- NEW YORK (AP) — Changes announced in corporate dividends Apr. 13-Apr. 17. INCREASED DIVIDENDS First Republic Bank .20 from .19 Johnson & Johnson 1.01 from .95 Procter & Gamble .7907 from .7459 REDUCED DIVIDENDS AGNC Investment .12(M) from .16(M) Apache Corp .025 from .25 Noble Energy .02 from .12 SM Energy .01(S) from .05(S) g- Canadian funds OTHER CORPORATE NEWS AND LISTINGS: STOCK SPLITS THIS WEEK Benitec Biopharma Ltd 3 for 2 China Recycling Energy Corp 1 for 10 reverse split Chesapeake Energy Corp 1 for 200 reverse split Cyclacel Pharmaceuticals Inc 1 for 20 reverse split Eagle Entertainment Inc 1 for 25 reverse split Mid-Con Energy Partners LP 1 for 20 reverse split Tough Built Industries Inc 1 for 10 reverse split NEW STOCK LISTINGS NASDAQ GLOBAL AND GLOBAL SELECT MARKETS Golub Capital BDC Inc rights STOCKS REMOVED FROM TRADING NYSE Quorum Health Corp
- 04/17/2020
|
70 Biggest Movers From Yesterday
- Gainers
Arcus Biosciences, Inc. (NASDAQ: RCUS) shares surged 89.4% to close at $29.50 on Thursday amid Bloomberg report that Gilead is holding talks to take a stake in company....
- 04/17/2020
|
Stocks That Hit 52-Week Highs On Wednesday
- On Wednesday morning, 15 companies hit new 52-week highs.
Areas of Significance:
Amazon.com (NASDAQ: AMZN) was the largest company by market cap to set a new 52-week...
- 04/15/2020
|
The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-Week Highs April 14)
Bio-Rad Laboratories, Inc...
- 04/15/2020
|
Cyclacel Announces Reverse Stock Split
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that effective at 5:00 p.m., Eastern Time, on April 14, 2020 (the “Effective Time”), the Company will effect a one-for-twenty reverse stock split of its outstanding common stock. The reverse stock split, which was unanimously approved by the Company’s Board of Directors, was approved by its stockholders at a Special Meeting of Stockholders held on October 28, 2019.
- 04/14/2020
|
Cyclacel Pharma Reports 1-For-20 Reverse Stock Split, Effective Apr. 14, 2020
|
When Will Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Breakeven?
- Cyclacel Pharmaceuticals, Inc.'s (NASDAQ:CYCC): Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical...
- 03/17/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune Bio (INMB)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune
- 03/12/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (NASDAQ: DVAX), Proteostasis Therapeutics (NASDAQ: PTI) and Inmune Bio (NASDAQ: INMB)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX
- 03/12/2020
|
Edited Transcript of CYCC earnings conference call or presentation 26-Feb-20 9:30pm GMT
- Q4 2019 Cyclacel Pharmaceuticals Inc Earnings Call
- 03/12/2020
|
Analysts Offer Insights on Healthcare Companies: Principia Biopharma (PRNB), Constellation Pharmaceuticals (CNST) and Protagonist Therapeutics (PTGX)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Principia Biopharma (PRNB), Constellation Pharmaceuticals
- 03/11/2020
|
Analysts Offer Insights on Healthcare Companies: Principia Biopharma (NASDAQ: PRNB), Constellation Pharmaceuticals (NASDAQ: CNST) and Protagonist Therapeutics (NASDAQ: PTGX)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Principia Biopharma
- 03/11/2020
|
Deciphera Pharmaceuticals (DCPH) Received its Third Buy in a Row
- After Nomura and Piper Sandler gave Deciphera Pharmaceuticals (NASDAQ: DCPH) a Buy rating last month, the company received another Buy, this time from
- 03/10/2020
|
Analysts Offer Insights on Healthcare Companies: DBV Technologies SA - American (DBVT) and Sutro Biopharma (STRO)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DBV Technologies SA - American (DBVT) and Sutro Biopharma
- 03/05/2020
|
Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (NASDAQ: DBVT) and Sutro Biopharma (NASDAQ: STRO)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DBV Technologies SA – American (
DBVT
–
Research Report
) and Sutro Biopharma (
STRO
–
Research Report
) with bullish sentiments.
DBV Technologies SA – Ame
- 03/05/2020
|
50 Healthcare Stocks Moving In Friday's Pre-Market Session
|
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Cyclacel Pharmaceuticals (CYCC) and Menlo Therapeutics (MNLO)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viking Therapeutics (VKTX), Cyclacel Pharmaceuticals (CYCC)
- 02/27/2020
|
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (NASDAQ: VKTX), Cyclacel Pharmaceuticals (NASDAQ: CYCC) and Menlo Therapeutics (NASDAQ: MNLO)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viking Therapeutics (
VKTX
–
Research Report
), Cyclacel Pharmaceuticals (
CYCC
–
Research Report
) and Menlo Therapeutics (
MNLO
–
Research Report
) with
- 02/27/2020
|
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
- – Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or.
- 02/26/2020
|
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 25)
Arcutis Biotherapeutics...
- 02/26/2020
|
Cyclacel Pharmaceuticals Q4 EPS $(0.17) Misses $(0.13) Estimate
|
Dell to sell RSA
- The company will sell its cyber security unit for $2.08 billion to a consortium led by Symphony Technology Group, Ontario Teachers’ Pension Plan Board and AlpInvest Partners.
- 02/24/2020
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
- Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. Merck ...
- 02/23/2020
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
|
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
- We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
- 02/20/2020
|
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
- We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
- 02/20/2020
|
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results
- BERKELEY HEIGHTS, N.J., Feb. 19, 2020 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- 02/19/2020
|
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year —…–9 Financial Results
|
Is Cyclacel Pharmaceuticals, Inc.'s (NASDAQ:CYCC) CEO Paid At A Competitive Rate?
- In 1997 Spiro Rombotis was appointed CEO of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC). This report will, first...
- 02/10/2020
|
Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference
- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the BIO CEO & Investor Conference at 11:15 a.m. EST on Monday, February 10, in the Wilder Room at the New York Marriott Marquis. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in its key programs. A live webcast of the presentation will be available through the Company's website: www.cyclacel.com.
- 02/03/2020
|
Cyclacel Pharmaceuticals to Present at the —…—… BIO CEO & Investor Conference
|
146 Biotechnology Stocks Moving In Thursday's Session
|
85 Biggest Movers From Yesterday
|
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2019 achievements and outlining the Company’s key business objectives for 2020. Cyclacel’s clinical and business strategy will be highlighted at a presentation during Biotech Showcase™ 2020 on Monday, January 13, 2019 at 9:30 a.m. PT in the Yosemite A Suite (Ballroom level) at the Hilton San Francisco Union Square. "During 2019 we have been excited to observe evidence of anticancer activity with CYC065, our CDK2/9 inhibitor, in patients with both solid and liquid cancers,” said Spiro Rombotis, President and Chief Executive Officer.
- 01/13/2020
|
41 Stocks Moving In Monday's Mid-Day Session
|
Cyclacel Pharmaceuticals shares are trading lower after the company announced it received a notice of delisting or failure to satisfy a continued listing rule or standard.
|
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech Showcase™ 2020, at 9:30 a.m. PT on January 13, in the Yosemite A (Ballroom level) at the Hilton San Francisco Union Square. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. A live webcast of the presentation will be available through the Company's website: www.cyclacel.com.
- 01/06/2020
|
Introducing Cyclacel Pharmaceuticals (NASDAQ:CYCC), The Stock That Tanked 92%
- This month, we saw the Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) up an impressive 99%. But that doesn't change the...
- 12/11/2019
|
Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
- BERKELEY HEIGHTS, N.J., Dec. 09, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing.
- 12/09/2019
|
38 Healthcare Stocks Moving In Monday's Pre-Market Session
|
Edited Transcript of CYCC earnings conference call or presentation 13-Nov-19 9:30pm GMT
- Q3 2019 Cyclacel Pharmaceuticals Inc Earnings Call
- 12/04/2019
|
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
|
The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
|
Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results
- – Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J.,.
- 11/13/2019
|
Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 EPS results.
|
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann —…–9 Healthcare Conference
|
Cyclacel Pharmaceuticals (CYCC) Investor Presentation - Slideshow
|
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
|
Stocks That Hit 52-Week Lows On Thursday
|
Stocks That Hit 52-Week Lows On Wednesday
|
Cyclacel Pharmaceuticals Q2 EPS $(0.11) Up From $(0.16) YoY
|
The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
- Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory submission for its recently approved gene therapy Zolgensma. The following are key biotech catalysts for the unfolding week. Conferences 2nd International Conference on Cardiovascular Diseases and Therapeutics: Aug. 12-13 in Amsterdam, Netherlands International Conference on Tuberculosis and Respiratory Diseases: Aug. 12-13 in London Wedbush PacGrow Healthcare Conference: Aug. 13-14 in New York City PDUFA Dates Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) awaits an FDA decision on its sNDA for Hetlioz, with the D-date fixed for Friday, Aug. 16. Hetlioz is being evaluated for jet lag disorder. Hetlioz received its first approval in January 2014 for non-24-hour sleep-wake disorder in blind people. KemPharm Inc (NASDAQ: KMPH ) is expected to submit its NDA for KP415, which is being evaluated for …
- 08/11/2019
|
Cyclacel Pharmaceuticals Announces First Patient Treated In Phase 1/2 Study Of Sapacitabine And Venetoclax In Relapsed Or Refractory AML Or MDS Patients
|
Mixed shelf filing roundup - healthcare
|
50 Biggest Movers From Friday
|
A Look At Benzinga Pro's Most-Searched Tickers For May 24
|
Cyclacel Pharmaceuticals Q1 EPS $(0.12) Beats $(0.2) Estimate
|
New Research: Key Drivers of Growth for Conatus Pharmaceuticals, MasTec, Cyclacel ...
|
Cyclacel Pharma Give an Updated From Phase 1 Data
|
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
|
The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO
|
Cyclacel Pharmaceuticals FY18 EPS $(0.62) vs $(1.95) In FY17, Collaboration, R&D Sales $150K
|
Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action
|
41 Stocks Moving In Monday's Mid-Day Session
|
Cyclacel Pharma shares are trading higher after the company announced an independent investigation was published on the company's treatment.
|
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
|
Cyclacel to Participate in '–st Annual ROTH Conference March –8-–9
|
Cyclacel Pharmaceuticals (CYCC) Presents At BIO CEO & Investor Conference - Slideshow
|
Cyclacel Pharmaceuticals to Present at the —…–9 BIO CEO & Investor Conference
|
Cyclacel Pharmaceuticals Says Approved Renewal Of Employment Agreements Of CEO Spiro Rombotis, CFO Paul Mcbarron
|
The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
|
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018
|
The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan
|
Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018
|
The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
|
Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018
|
The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
|
Consolidated Research: —…–8 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, ...
|
Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018
|
Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018
|
The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal
|
Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018
|
The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut
|
Cyclacel Pharmaceuticals Q3 EPS $(0.18) Misses $(0.17) Estimate
|
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
|
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
|
Cyclacel Pharmaceuticals (CYCC) Presents At DAWSON JAMES 4th Annual Small Cap Growth Conference - Slideshow
|
UPDATE: Cyclacel Spokesperson Iterated Co. Itself Will Not Be Presenting Data For Cystic Fibrosis Treatment
|
Premarket Losers as of 9:05 am (10/5/2018)
|
Cyclacel Pharma 8-K Shows $5M At-The-Market Offering
|
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann —…–8 Healthcare Conference
|
Your Daily Scoop: Five Prime Progresses, Endocyte's rPFS And Stock Offering, Tracon's Results Published
|
Cyclacel Pharmaceuticals Starts Phase 1b/2 Clinical Trial Of Sapacitabine With Olaparib, Study Will Enroll ~64 Patients
|
